Reference : Levels of C-reactive protein are associated with response to infliximab therapy in pa...
Scientific journals : Article
Human health sciences : Gastroenterology & hepatology
Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease.
Jurgens, Matthias [> > > >]
Mahachie John, Jestinah mailto [> > > >]
Cleynen, Isabelle [> > > >]
Schnitzler, Fabian [> > > >]
Fidder, Herma [> > > >]
van Moerkercke, Wouter [> > > >]
Ballet, Vera [> > > >]
Noman, Maja [> > > >]
Hoffman, Ilse [> > > >]
van Assche, Gert [> > > >]
Rutgeerts, Paul J [> > > >]
Van Steen, Kristel mailto [Université de Liège - ULiège > Dép. d'électric., électron. et informat. (Inst.Montefiore) > Bioinformatique >]
Vermeire, Severine [> >]
Clinical Gastroenterology and Hepatology: the Official Clinical Practice Journal of the American Gastroenterological Association
Yes (verified by ORBi)
[en] Adult ; Antibodies, Monoclonal/administration & dosage ; Biological Markers/blood ; C-Reactive Protein/analysis ; Cohort Studies ; Crohn Disease/diagnosis/drug therapy/pathology ; Drug Monitoring/methods ; Female ; Humans ; Immunologic Factors/administration & dosage ; Male ; Mucous Membrane/pathology ; Treatment Outcome
[en] BACKGROUND & AIMS: Infliximab is an antibody against tumor necrosis factor-alpha that is used to treat patients with moderate to severe Crohn's disease (CD). C-reactive protein (CRP) is a marker used to identify and follow individuals with CD. We analyzed changes in levels of CRP in a large cohort of patients with CD undergoing treatment with infliximab. METHODS: Serial levels of CRP were analyzed in 718 CD patients. Blood was collected before each infusion; a total of 8845 CRP levels were available for analysis. The correlations between CRP levels and need for dose adjustment, outcomes, and mucosal healing (based on endoscopic analysis of 253 patients) were evaluated. Therapy adjustment was considered successful if therapy continued without need for change. Subgroup analysis was performed by using data from 268 patients who received 8 weeks of maintenance therapy. RESULTS: More patients with high baseline levels of CRP responded to infliximab than patients with normal levels (90.8% vs 82.6%; P = .014). Early normalization of CRP levels correlated with sustained long-term response (P < .001). CRP levels remained significantly higher among patients who lost their response to infliximab, compared with those with a sustained response (P = .001). At time of loss of response, CRP levels were significantly increased (median, 11.2 mg/L) and did not return to baseline levels (median, 18.2 mg/L; P = .039). CRP correlated with mucosal healing (P = .033). CONCLUSIONS: CRP is a good marker of disease activity in patients treated with infliximab. Increased levels of CRP indicate mucosal inflammation and a likelihood of clinical relapse.
Copyright (c) 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.

File(s) associated to this reference

Fulltext file(s):

Restricted access
Jurgens2011.pdfAuthor postprint1.53 MBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.